GLP-1 Medications and Michigan Medicare Coverage: What Changed in 2026

The Medicare GLP-1 Bridge Program: A Historic First

On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare GLP-1 Bridge, the first-ever federal program allowing Medicare Part D beneficiaries to access GLP-1 receptor agonist medications for weight management at a fixed cost of just $50 per month. This is a seismic shift. Until now, Medicare was statutorily prohibited from covering drugs prescribed solely for weight loss, leaving millions of older adults to pay out of pocket for medications that can cost over $1,000 monthly at retail prices.

The Bridge program is a temporary demonstration running through December 2027. It covers FDA-approved GLP-1 medications indicated for chronic weight management, including semaglutide (Wegovy) and tirzepatide (Zepbound). Medications prescribed solely for type 2 diabetes, such as Ozempic and Mounjaro, are already covered under standard Part D benefits and are handled separately.

Who Is Eligible for the Medicare GLP-1 Bridge?

To qualify for the Bridge program, Medicare beneficiaries must meet the following criteria:

• Enrolled in a Medicare Part D plan (either standalone or through a Medicare Advantage plan with drug coverage)
• BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• Prescribed by an eligible provider who documents the medical necessity and agrees to the program's prescribing guidelines

There are important limitations. The program has capacity constraints, meaning not every eligible beneficiary may gain immediate access. CMS has indicated it will prioritize beneficiaries with the highest clinical need. The Bridge is also distinct from the broader BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health), a CMS Innovation Center demonstration announced in January 2026 that aims to create a longer-term framework for GLP-1 access in both Medicare and Medicaid. The BALANCE Model is still in its early implementation phase and may reshape coverage further in 2027 and beyond.

The TREAT Act: Permanent Coverage on the Horizon?

While the Bridge program is temporary, Congress is considering a permanent solution. The Treat and Reduce Obesity Act (TROA) was reintroduced in the 119th Congress in 2025 as both H.R. 4231 and S. 1973. This bipartisan legislation would amend the Social Security Act to require Medicare Part D to cover FDA-approved anti-obesity medications, removing the longstanding statutory exclusion once and for all.

The TREAT Act has broad support from medical societies and patient advocacy organizations, but it has not yet passed. If enacted, it would make GLP-1 coverage a standard Medicare benefit rather than a time-limited demonstration, providing stability for the millions of older Americans living with obesity.

Michigan Medicaid Took the Opposite Path

While Medicare expanded access at the federal level, Michigan's Medicaid program moved in the other direction. Effective January 1, 2026, the Michigan Department of Health and Human Services significantly restricted GLP-1 coverage for Medicaid beneficiaries. The state projected savings of approximately $240 million from the policy change.

Before January 2026, Michigan Medicaid covered GLP-1 medications for weight management for patients with a BMI of 30 or greater, or a BMI of 27 or greater with at least one obesity-related comorbidity. Under the new restrictions, coverage for weight management purposes is now limited to patients who meet one of two criteria:

• A diagnosis of type 2 diabetes, where GLP-1 medications serve a dual purpose of glycemic control and weight management
• A BMI of 40 or greater (morbid obesity), with prior authorization required

This means tens of thousands of Michigan Medicaid members with a BMI between 27 and 39.9 who were previously receiving GLP-1 therapy for weight management lost coverage at the start of 2026. According to experts at the University of Michigan Institute for Healthcare Policy and Innovation, this policy creates a difficult clinical situation: patients may be taken off medications that were working, potentially leading to weight regain and worsening of obesity-related conditions.

What the Research Shows About GLP-1 Coverage and Cost

The policy debate around GLP-1 Medicare coverage in Michigan and nationwide is informed by a growing body of research. According to PubMed, a 2025 fiscal impact analysis published in JAMA Health Forum estimated that expanded Medicare coverage of GLP-1 receptor agonists for obesity would cost approximately $65.9 billion in drug costs over 10 years, offset by $18.2 billion in health care savings from reduced obesity-related complications such as heart disease, stroke, and diabetes. The study's authors noted that even moderate uptake would produce meaningful clinical benefits, but emphasized that further drug price reductions are essential for fiscal sustainability (DOI: 10.1001/jamahealthforum.2025.0905).

Additionally, a 2026 synopsis published in the Annals of Internal Medicine from a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop highlighted that coverage decisions for GLP-1 medications remain highly variable across Medicare, Medicaid, and private payers. The workshop concluded that real-world evidence is essential for developing value-based coverage policies as GLP-1 utilization continues to expand rapidly (DOI: 10.7326/ANNALS-25-05468).

Falling Through the Gaps: What Are Your Options?

The reality in Michigan right now is that many patients find themselves in a coverage gap. If you are on Medicare and do not meet the Bridge program's criteria or cannot secure a spot, or if you are on Medicaid with a BMI under 40 and no diabetes diagnosis, you may be left without an affordable path to GLP-1 therapy through insurance alone.

This is where specialized clinics can make a real difference. At Arbour Longevity in Ann Arbor, we work with patients across all insurance situations to provide medically supervised weight loss programs that are both effective and affordable. Our approach includes:

• Comprehensive metabolic evaluation to identify the right treatment pathway for your body
• Access to GLP-1 and other evidence-based weight loss medications at competitive, transparent pricing
• Ongoing clinical support from Gandhi Bhattarai, FNP-BC, PMHNP-BC, a triple board certified nurse practitioner with expertise in longevity, metabolic health, and regenerative medicine
• Lifestyle and nutritional guidance integrated into your treatment plan for sustainable results

Whether you are navigating insurance barriers or simply want a medically guided approach to weight management, our clinic is here to help you access the care you need without the bureaucratic runaround.

Frequently Asked Questions

Does Medicare cover Wegovy or Zepbound for weight loss in Michigan in 2026?

Yes, as of July 1, 2026, the new Medicare GLP-1 Bridge program allows eligible Medicare Part D beneficiaries to access Wegovy (semaglutide) and Zepbound (tirzepatide) for weight management at a fixed cost of $50 per month. You must have a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related comorbidity, and receive a prescription from an eligible provider. The program runs through December 2027.

Does Michigan Medicaid still cover GLP-1 medications for weight loss?

Michigan Medicaid significantly restricted GLP-1 coverage for weight management effective January 1, 2026. Coverage is now limited to patients with type 2 diabetes or a BMI of 40 or greater. Patients with a BMI between 27 and 39.9 who were previously covered for weight management alone are no longer eligible unless they have a qualifying diabetes diagnosis.

What if I do not qualify for Medicare or Medicaid GLP-1 coverage?

Patients who fall outside insurance coverage can still access GLP-1 medications through specialized clinics that offer competitive self-pay pricing and comprehensive weight management support. Arbour Longevity in Ann Arbor provides medically supervised weight loss programs with transparent pricing and personalized care, making treatment accessible even without insurance coverage.

Will Medicare permanently cover GLP-1 medications for obesity?

Not yet. The Medicare GLP-1 Bridge is a temporary demonstration program ending in December 2027. However, the bipartisan Treat and Reduce Obesity Act (TROA), currently before Congress, would make Medicare coverage of FDA-approved anti-obesity medications permanent if passed. The outcome of this legislation will determine long-term access for millions of Medicare beneficiaries.

Arbour Longevity is a longevity, hormone and regenerative medicine clinic at 2217 Packard St #15, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm. Care is provided by Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC, triple board certified in family practice, psychiatric mental health, and anti-aging and functional medicine. Your first visit is $35, applied toward your treatment plan. Book your $35 consultation or call (734) 436-3357.